The Lancet Gastroenterology & Hepatology
@LancetGastroHep
Followers
27K
Following
2K
Media
3K
Statuses
10K
The Lancet Gastroenterology & Hepatology is the world-leading #gastroenterology and #hepatology research journal. IF=38.6.
Joined February 2016
We are the world-leading journal dedicated to gastroenterology & hepatology research and review. While a partial measurement of our impact, we are pleased to share our 2024 Impact Factor is 38·6 & our Scopus CiteScore is 51·1. https://t.co/jeKZS7j7SX
#GITwitter #LiverTwitter
1
2
22
Our January 2026 issue is out now: https://t.co/bK6A0hWWqa Content includes #MASH, #IBD, #PBC, #PSC, #ageing, #diet + more! #GITwitter #MedTwitter #LiverTwitter
0
7
12
New research - Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial https://t.co/2koAejfBJG
#GITwitter #OncTwitter @OncoAlert
0
2
6
New research - Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12Cmutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials https://t.co/sqz0ak9xfr
#OncTwitter #GITwitter
0
1
7
New research - Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial https://t.co/xOW4LFIVrT
#GITwitter #LiverTwitter #OncTwitter
1
2
9
New Comment - Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease https://t.co/ODPoimo8Ya
#GITwitter #MedTwitter
thelancet.com
Inflammatory bowel disease (IBD) has expanded beyond its initial confines of early industrialised countries in North America, Europe, and Oceania and now constitutes a global illness. Once rare in...
0
4
13
🚨Our Dec issue is live! - https://t.co/jtWFJdoTSE 📊Articles: #lungcancer, #breastcancer, #hepatocellularcarcinoma, #rectalcancer, #glioma 📑Reviews including neurocognitive outcomes in patients with brain metastases AND SISAQOL-IMI consensus guidelines on PROs in trials
0
9
19
New research - Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial https://t.co/GCF8tpjMHN
#GITwitter #MedTwitter
0
2
10
New @LancetDigitalH - Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study https://t.co/GHxMU5Za2c
#LiverTwitter #MedTwitter
thelancet.com
We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance the accuracy of the prediction of progression to death in DCD donors and...
1
3
12
New Comment - The essential medicines list for inflammatory bowel disease: time to raise the standards of global care https://t.co/TSPOZkDPn0
#GITwitter #MedTwitter
0
0
8
New @eClinicalMed - Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study https://t.co/2GWg2uVr5P
#GITwitter #IDTwitter #MedTwitter
thelancet.com
This study shows global heterogeneity in MDRO carriage among patients undergoing ERCP, reflecting underlying differences in antimicrobial resistance, healthcare infrastructure, and infection control...
0
1
7
New @eClinicalMed - Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis https://t.co/EijKJI2ehg
#GITwitter #LiverTwitter #MedTwitter #EndoTwitter
thelancet.com
GLP-1 RAs, particularly Semaglutide and liraglutide, reduce alcohol use as measured by AUDIT scores and show beneficial effects on consumption, relapse, and alcohol-related morbidity. Mechanistic...
0
11
48
New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities https://t.co/wGtsc7XUQ2
#GITwitter #MedTwitter
thelancet.com
Treatment efficacy in similar WH and SA IBD patients recruited to the UK IBD BioResource is unaffected by ethnicity but patients from SA ethnic backgrounds are at increased risk of developing...
0
6
23
New Comment - Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity https://t.co/zHRENgEq6A
#OncTwitter #GITwitter
thelancet.com
Worldwide, colorectal cancer is the second leading cause of cancer-related mortality and the third most common cancer, with incidence rates increasing among individuals younger than 50 years.1...
1
8
22
New research - Safety & pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF & interleukin-23 in healthy participants & patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial https://t.co/QDIlYQQBkW
#GITwitter
thelancet.com
The favourable safety profile and preliminary evidence for efficacy support development of SOR102 for treatment of ulcerative colitis.
0
0
21
NEW Research: Digital cognitive behavioural self-management programme for fatigue, pain, and faecal incontinence in inflammatory bowel disease (IBD-BOOST): a multicentre, parallel, randomised controlled trial. Read it here: https://t.co/GQA1wRHQcN
1
6
4
New @TheLancet - Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study https://t.co/g7dwo3gsTO
#LiverTwitter #MedTwitter
thelancet.com
Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of...
0
6
23
🆕The human crisis in cancer: a Lancet Oncology Commission is now live! The commission warns of a growing human crisis in cancer and calls for a shift towards human-centered care 🖱️Read the Commission here: https://t.co/q4vSzUHLzk
0
10
18
📽️Watch video on The Human Crisis in Cancer here: https://t.co/r2VCnOU1fA 🎧 In our podcast, Dr Gary Rodin, @gary_rodin, joins us in discussing the Commission: https://t.co/zwluRcwf05
🆕The human crisis in cancer: a Lancet Oncology Commission is now live! The commission warns of a growing human crisis in cancer and calls for a shift towards human-centered care 🖱️Read the Commission here: https://t.co/q4vSzUHLzk
1
10
15
🌏 Endometriosis affects around 190 million women and girls globally. Despite progress, the exact causes remain unknown. The latest issue of The Lancet Obstetrics, Gynaecology & Women’s Health features content on recent advancements & ares for further research. 🔗 :
12
126
296
NEW RESEARCH—IgG4-related disease in the Japanese population: a whole-genome sequencing study https://t.co/n0mSum5MAX Plus, linked Comment https://t.co/phVRZLnR6S
0
3
7